Nectin Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10M

  • Investors
  • 12

Nectin Therapeutics General Information

Description

Operator of a biotechnology company intended to treat solid and hematological malignancies. The company develops antibodies that overcome inhibitory pathways deployed by the tumors and help immune cells to effectively destroy cancer cells, enabling medical professionals to improve patient's lives with therapeutic options.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Hi-Tech Campus Givat Ram
  • POB 39135
  • Jerusalem 91390
  • Israel
+972
Primary Industry
Biotechnology
Corporate Office
  • Hi-Tech Campus Givat Ram
  • POB 39135
  • Jerusalem 91390
  • Israel
+972

Nectin Therapeutics Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nectin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 06-May-2024 $10M Completed Pre-Clinical Trials
8. Accelerator/Incubator 01-Jan-2024 Completed Pre-Clinical Trials
7. Grant 08-Nov-2023 Completed Clinical Trials - Phase 1
6. Later Stage VC 17-May-2023 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 23-Feb-2022 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 01-May-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 15-Jul-2020 Completed Clinical Trials - Phase 1
2. Seed Round 01-Jan-2017 $1M $1M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Nectin Therapeutics’s complete valuation and funding history, request access »

Nectin Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred A
Preferred Seed
To view Nectin Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Nectin Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to treat solid and hematological malignancies. The company develops antibod
Biotechnology
Jerusalem, Israel
11 As of 2022

South San Francisco, CA
 

Somerville, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nectin Therapeutics Competitors (6)

One of Nectin Therapeutics’s 6 competitors is Nkarta Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Kite Pharma Formerly VC-backed Santa Monica, CA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
To view Nectin Therapeutics’s complete competitors history, request access »

Nectin Therapeutics Patents

Nectin Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023346641-A1 Humanized antibodies against nectin-4 and drug conjugates thereof Pending 20-Sep-2022
EP-4590401-A1 Humanized antibodies against nectin-4 and drug conjugates thereof Pending 20-Sep-2022
US-20260014269-A1 Humanized antibodies against nectin-4 and drug conjugates thereof Pending 20-Sep-2022
WO-2024062476-A1 Humanized antibodies against nectin-4 and drug conjugates thereof Inactive 20-Sep-2022
AU-2023331612-A1 Drug conjugates of humanized anti pvr antibodies Pending 04-Sep-2022 A61K47/6851
To view Nectin Therapeutics’s complete patent history, request access »

Nectin Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nectin Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Yissum Accelerator/Incubator
European Innovation Council Accelerator/Incubator Minority
Cancer Focus Fund Venture Capital Minority
Guangzhou Sino-Israel Bio-Industry Investment Fund Venture Capital Minority
IFB Group Corporation Minority
You’re viewing 5 of 12 investors. Get the full list »

Nectin Therapeutics FAQs

  • When was Nectin Therapeutics founded?

    Nectin Therapeutics was founded in 2017.

  • Where is Nectin Therapeutics headquartered?

    Nectin Therapeutics is headquartered in Jerusalem, Israel.

  • What is the size of Nectin Therapeutics?

    Nectin Therapeutics has 11 total employees.

  • What industry is Nectin Therapeutics in?

    Nectin Therapeutics’s primary industry is Biotechnology.

  • Is Nectin Therapeutics a private or public company?

    Nectin Therapeutics is a Private company.

  • What is Nectin Therapeutics’s current revenue?

    The current revenue for Nectin Therapeutics is .

  • How much funding has Nectin Therapeutics raised over time?

    Nectin Therapeutics has raised $58M.

  • Who are Nectin Therapeutics’s investors?

    Yissum, European Innovation Council, Cancer Focus Fund, Guangzhou Sino-Israel Bio-Industry Investment Fund, and IFB Group are 5 of 12 investors who have invested in Nectin Therapeutics.

  • Who are Nectin Therapeutics’s competitors?

    Nkarta Therapeutics, Genetix Biotherapeutics, Inovio Pharmaceuticals, Kite Pharma, and Immunocore Holdings are some of the 6 competitors of Nectin Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process